TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis
Kidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/12/1485 |
| _version_ | 1797455767131914240 |
|---|---|
| author | Cheol Ho Park Tae-Hyun Yoo |
| author_facet | Cheol Ho Park Tae-Hyun Yoo |
| author_sort | Cheol Ho Park |
| collection | DOAJ |
| description | Kidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-β1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-β1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-β1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-β1 inhibitors in CKD management. |
| first_indexed | 2024-03-09T15:59:13Z |
| format | Article |
| id | doaj.art-423fd4ed22aa42d1ad4be7954c6816a6 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T15:59:13Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-423fd4ed22aa42d1ad4be7954c6816a62023-11-24T17:15:59ZengMDPI AGPharmaceuticals1424-82472022-11-011512148510.3390/ph15121485TGF-β Inhibitors for Therapeutic Management of Kidney FibrosisCheol Ho Park0Tae-Hyun Yoo1Department of Internal Medicine, Institute of Kidney Disease Research, College of Medicine, Yonsei University, Seodaemun-gu, Seoul 03722, Republic of KoreaDepartment of Internal Medicine, Institute of Kidney Disease Research, College of Medicine, Yonsei University, Seodaemun-gu, Seoul 03722, Republic of KoreaKidney fibrosis is a common pathophysiological mechanism of chronic kidney disease (CKD) progression caused by several underlying kidney diseases. Among various contributors to kidney fibrosis, transforming growth factor-β1 (TGF-β1) is the major factor driving fibrosis. TGF-β1 exerts its profibrotic attributes via the activation of canonical and non-canonical signaling pathways, which induce proliferation and activation of myofibroblasts and subsequent accumulation of extracellular matrix. Over the past few decades, studies have determined the TGF-β1 signaling pathway inhibitors and evaluated whether they could ameliorate the progression of CKD by hindering kidney fibrosis. However, therapeutic strategies that block TGF-β1 signaling have usually demonstrated unsatisfactory results. Herein, we discuss the therapeutic concepts of the TGF-β1 signaling pathway and its inhibitors and review the current state of the art regarding regarding TGF-β1 inhibitors in CKD management.https://www.mdpi.com/1424-8247/15/12/1485TGF-βkidneyfibrosis |
| spellingShingle | Cheol Ho Park Tae-Hyun Yoo TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis Pharmaceuticals TGF-β kidney fibrosis |
| title | TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis |
| title_full | TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis |
| title_fullStr | TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis |
| title_full_unstemmed | TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis |
| title_short | TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis |
| title_sort | tgf β inhibitors for therapeutic management of kidney fibrosis |
| topic | TGF-β kidney fibrosis |
| url | https://www.mdpi.com/1424-8247/15/12/1485 |
| work_keys_str_mv | AT cheolhopark tgfbinhibitorsfortherapeuticmanagementofkidneyfibrosis AT taehyunyoo tgfbinhibitorsfortherapeuticmanagementofkidneyfibrosis |